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Abstract  1 
In an alternative approach for radiotracer design, a photoactivatable HBED-CC-PEG3-ArN3 2 
chelate was synthesised and photoconjugated to the anti-c-MET antibody MetMAb 3 
(onartuzumab). Photoconjugation gave the functionalised protein HBED-CC-azepin-MetMAb 4 
with a photochemical conversion of 18.5±0.5% (n = 2) which was then radiolabelled with 68Ga3+ 5 
ions. The purified and formulated [68Ga]GaHBED-CC-azepin-MetMAb radiotracer was evaluated 6 
in vitro and in vivo. Standard stability tests and cellular binding assays confirmed that the 7 
radiotracer remained radiochemically pure and immunoreactive after photochemical conjugation. 8 
[68Ga]GaHBED-CC-azepin-MetMAb showed specific uptake in c-MET-positive MKN-45 (high-9 
expression) and PC-3 (low/moderate expression) tumours with tumour-associated activities at 6 h 10 
post-administration of 10.33±1.27 (n = 5) and 3.88±1.27 (n = 3) %ID/g, respectively. In 11 
competitive blocking experiments, MKN-45 tumour uptake was reduced by approximately 55% 12 
(P-value < 0.001 compared with non-blocked experiments) confirming specific radiotracer 13 
binding to c-MET in vivo. Radiochemical, cellular and in vivo experiments confirmed that the 14 
photoradiochemical approach is a viable tool to synthesise new radiotracers for immuno-PET.  15 
 16 
Keywords: 68Ga, photoradiochemistry, immuno-PET, hepatocyte growth factor receptor (c-17 
MET), MetMAb 18 
 19 
 20 





Antibody-based PET imaging (immuno-PET) is an invaluable tool for cancer diagnosis and further 23 
monitoring of the efficacy and patient response to chemotherapy. Accessing radiolabeled 24 
antibodies in a clinical setting relies on traditional bioconjugation methods which usually involve 25 
protein ligation at lysine or cysteine residues using amide, thioester and maleimide thiol coupling 26 
reactions. Until recently, only a handful of studies had investigated the use of photochemical 27 
conjugation methods in radiotracer synthesis.1–1011 In 2019, our group demonstrated that 28 
photochemical activation of chelates bearing aryl azide groups gave efficient conjugation and 29 
radiolabelling to monoclonal antibodies forming viable radiotracers for immuno-PET.12,13 In this 30 
work, we sought to extend this photoradiochemical approach to engineered immunoglobulins by 31 
conjugating the c-MET targeting antibody MetMAb with the novel acyclic photoactive chelate 32 
HBED-CC-PEG3-ArN3. We report the synthesis of HBED-CC-PEG3-ArN3 and its applications in 33 
rapid and efficient photochemical bioconjugation. The HBED-CC-azepin-MetMAb conjugate was 34 
radiolabeled with 68Ga to produce an immuno-PET radiotracer which was investigated in vitro and 35 
in vivo.  36 
Human hepatocyte growth-factor receptor (c-MET) is a receptor tyrosine kinase which is 37 
expressed on the surface of many epithelial cells and belongs to the MET family.14 Hepatocyte 38 
growth factor (HGF; also known as scatter factor [SF]) is the only known natural ligand for c-39 
MET.15 Binding of active HGF to c-MET results in receptor dimerisation and internalisation which 40 
induces cell signalling.15 The c-MET signalling pathway is dysregulated in a number of human 41 
cancers including gastric, breast, lung, ovarian and pancreatic cancer.16 Overexpression and 42 
amplification of the c-MET gene induces signaling cascades that influence tumour cell 43 




MET antibodies show some promise in the clinical treatment of MET associated cancers but such 45 
agents are yet to receive regulatory approval.17 Molecular imaging of c-MET expression has the 46 
potential to support the clinical evaluation of MET-targeted therapies by assisting in patient 47 
selection and in monitoring drug efficacy.18–20 48 
 MetMAb (onartuzumab, Genentech Inc., South San Francisco, CA) contains a humanized 49 
one-armed monovalent anti-MET antibody designed to bind the extracellular domain of c-MET 50 
and thereby block activation by HGF.21,22 MetMAb has been investigated in phase III trials as a 51 
treatment for non-small-cell lung cancer (NSCLC).21 The antibody component, onartuzumab, was 52 
constructed using “knobs into holes” technology and a one-armed design was employed to prevent 53 
the dimerisation of the c-MET receptor upon binding, thereby avoiding the activation of signal 54 
transduction.19,21  55 
 Recent work using onartuzumab coupled to 89Zr and 76Br radionuclides via standard 56 
isothiocyanate conjugation techniques or direct bromination of tyrosine residues respectively 57 
illustrated the utility of MetMAb as an immuno-PET agent for imaging c-MET.19,20 These initial 58 
studies indicate the ability of a MetMAb radiotracer to distinguish between tumours with high 59 
(MKN-45) and low (U87-MG) c-MET expression.19 Prior success in using MetMAb to develop 60 
radiotracers for immuno-PET confirms that this modified antibody is a suitable benchmark for 61 
evaluating if photoradiochemistry can be applied to engineered proteins. 62 
 63 
Results and Discussion 64 





Scheme 1. Synthetic route toward HBED-CC-PEG3-ArN3 (1). 67 
 68 
The synthesis of HBED-CC-PEG3-ArN3 (1) is depicted in Scheme 1. Full synthetic details and 69 
characterisation data are reported in the supplementary information (Supporting Figures 1 – 2, and 70 
9 – 18). Briefly, the protected ester, HBED-CC(OtBu)3, (4) was synthesised in 5 linear steps from 71 
compounds 10 and 11 in a procedure adapted from Zha et al.23 Synthesis of the NH2-PEG3-ArN3 72 
(3) was as previously described.12 The protected chelate (4) was coupled to the aryl azide (3) via 73 
standard amide coupling. Tert-butyl protecting groups were cleaved using trifluoroacetic acid to 74 
yield HBED-CC-PEG3-ArN3 (1) in an overall yield of 5.5%. The HBED-CC chelate is a hexa-75 
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photoactive chelate (1) was moderately soluble in water (»1 mM), and solubility improved (»2.5 77 
mM) under basic conditions. 78 
 The photoactive properties of compound 1 were investigated by the means of 79 
photochemical degradation experiments. Solutions of compound 1 were irradiated (LED intensity 80 
50% [full power = 92 mW], 365 nm) and aliquots of the irradiated solution were analysed by 81 
HPLC at various time points (Supporting Figure 2). Experiments confirmed that compound 1 was 82 
photoactive and kinetic studies determined that under the conditions employed, photodegradation 83 
was complete in <10 min as indicated by complete consumption of starting material 1.  84 
 85 
Photochemical conjugation 86 
87 
Scheme 2. Reaction scheme showing the sequential photochemical conjugation and 88 



























































The two-step photoradiochemical method is shown in Scheme 2. Previous mechanistic studies 91 
showed that nucleophilic attack by a primary amine group of a protein on the photo-induced 92 
ketenimine intermediate yields a stable covalent conjugated protein via formation of a 7-membered 93 
heterocyclic azepine ring.25  94 
 The antibody component of MetMAb was recovered in sterile saline and was incubated 95 
with a 5-fold excess of HBED-CC-PEG3-ArN3 (1) at room temperature under basic conditions at 96 
pH 8 – 9. The reaction was irradiated for 10 min. then excess chelate was removed by multiple 97 
centrifugal filtration cycles. Aliquots of the crude photochemical conjugation reactions were 98 
retained prior to purification and subsequently radiolabelled with 68Ga to determine the 99 
photochemical conversion (PCC). Radiolabelled samples were analysed by radioactive-size-100 
exclusion chromatography (radio-SEC) with a mobile phase of PBS (Gibco, pH 7.4) and decay-101 
corrected chromatograms were integrated to determine the ratio of labelled protein to excess 68Ga-102 
complexes. Subsequent radio-SEC analysis gave a photoradiochemical conversion of 18.5±0.5 % 103 
(n = 2). If it assumed that compound 1 and the metallated [68Ga]Ga(1) complex have equivalent 104 
photochemical initiation and conjugation efficiencies, then with an initial 5-fold excess the 105 
estimated upper-limit to the number of bound and chemically accessible chelates per antibody was 106 
0.93±0.03. In practice, the reactivity and PCC between free chelates and metallated complexes is 107 
different. The actual chelate-to-antibody ratio in the final product is likely to be lower and depends 108 
strongly on the initial specific activity and radiochemical purity of the radionuclide source. 109 
            Liquid chromatography mass spectrometry (LCMS) analysis using time-of-flight (TOF) 110 
measurements of the photochemically conjugated MetMAb was also conducted. From these data, 111 
a shift in the mass spectrum was observed corresponding to one chelate modification (Supporting 112 




 Photochemical conjugation experiments using MetMAb in formulation buffer (10 nmol L-114 
1 histidine succinate, 106 nmol L-1 trehalose dihydrate, 0.02% polysorbate 20, pH 5.7) rather than 115 
pre-purified in saline were also conducted.21 Under equivalent photochemical and radiolabelling 116 
conditions, [68Ga]GaHBED-CC-azepin-MetMAb was still obtained from fully formulated samples 117 
of MetMAb but the PCC reduced to ~10%. Reduced PPC is likely due to the presence of histidine 118 
in the formulation buffer which competes with MetMAb lysine residues for nucleophilic attack on 119 
the ketenimine intermediate. Nevertheless, successful photochemical conjugation and 120 
radiolabelling direct from a formulated protein source is unprecedented and illustrates one of the 121 
potential advantages of using our photoradiochemical approach over existing methods.  122 
 Many existing bioconjugation techniques are inefficient and require a large excess of 123 
chelate due to aqueous instability of activated NHS or TFP esters.26 Furthermore, many activated 124 
chelates are poorly soluble in aqueous conditions and require addition of organic solvents (e.g. 125 
DMSO/EtOH) which can result in degradation or precipitation of biomolecules. The 126 
photochemical approach has the advantages that the reaction is fast (~10 min.), and that the 127 
derivatised chelate is water soluble and stable as a stock solution when protected from light. The 128 
reaction is also relatively efficient, and reproducible with only 5-fold excess of chelate required to 129 
produce a bioconjugate with sufficiently high molar activity for in vivo experiments.  130 
 131 
Photoradiosynthesis of [68Ga]GaHBED-CC-azepin-MetMAb 132 
 [68Ga][Ga(H2O)6]Cl3(aq.) was obtained by elution of a 68Ge/68Ga-generator with HCl (0.1 M). All 133 
68Ga-labelling experiments were performed in acetate buffer (0.25 M, pH 4.4) at room temperature. 134 
Radio-TLC methods using a citrate eluent (pH 4) were used to follow the course of all radioactive 135 





Figure 1. A) Radio-iTLC data for [68Ga]GaHBED-CC-PEG3-ArN3 species, control samples, and 138 
subsequent photochemical conjugation to MetMAb. B) PD-10 elution profiles showing the 139 
analysis of the photochemical conjugation and 68Ga-radiolabelling of HBED-CC-PEG3-ArN3 to 140 
MetMAb. C) Electronic absorption and radio-SEC-HPLC data showing chromatograms for 141 
[68Ga]GaHBED-CC-azepin-MetMAb and related controls. 142 
 143 
 Figure 1 shows the radio-iTLC profiles of the control, [68Ga][Ga(citrate)2]3- (Rf = 1.0), 144 
[68Ga]Ga(1) (Rf = 0.03 – 0.32; green trace), irradiated [68Ga]Ga(1) (red trace), the 68Ga-145 
radiolabeled crude photochemical conjugation (blue trace), and the purified [68Ga]GaHBED-CC-146 
azepin-MetMAb (Rf = 0.0; black trace) radiotracer in panel A. Irradiation of [68Ga]Ga(1) results 147 
in three peaks on radio-TLC, with one of these migrating to the solvent front (Rf = 1.0). This result 148 
can be explained by the number of different polar species generated by irradiation of compound 149 
(1) as shown in Supporting Figure 2. Radio-iTLC in a different eluent system (MeOH/H2O 1:1) 150 
showed that this peak at the solvent front was not associated with “free” 68Ga3+ ions, which in this 151 
solvent system was retained at the baseline as [68Ga][Ga(OH)3]. 152 
  Two different size exclusion chromatography (SEC) methods were used to measure decay 153 
corrected radiochemical purity (RCP) and yields. PD-10 SEC was used for preparative purification 154 
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prior to in vitro and in vivo experiments. PD-10 elution profiles of irradiated [68Ga]Ga(1), the 68Ga-155 
radiolabeled crude photochemical conjugation (RCP = 24%), and the purified [68Ga]GaHBED-156 
CC-azepin-MetMAb (RCP = 93%) are shown in Figure 1B. Data confirm that a portion of the 157 
68Ga-radioactivity in the crude mixtures eluted with the high molecular weight protein fraction. 158 
However, due the overlapping elution profiles of irradiated [68Ga]Ga(1) (red trace) and the crude 159 
68Ga-radiolabeled product (blue trace) in analytical PD-10 SEC methods, we used high 160 
performance liquid chromatography (radio-SEC-HPLC, coupled to a BioRad 650 ENrich column) 161 
to determine accurate values for the RCP. The UV-SEC (280 nm) trace of native MetMAb and the 162 
radio-SEC-HPLC traces of irradiated [68Ga]Ga(1), the 68Ga-radiolabeled crude photochemical 163 
conjugation (RCP = 19%), and the purified [68Ga]GaHBED-CC-azepin-MetMAb (RCP >95%) are 164 
shown in Figure 1C.  165 
 The molar activity of [68Ga]GaHBED-CC-azepin-MetMAb was estimated as 35.8±2.00 166 
MBq nmol-1 (n = 8) as measured by titrations of [68Ga]GaHBED-CC-azepin-MetMAb against a 167 
68Ga stock solution of known molar activity. After purification by preparative PD-10 SEC, high 168 
purity [68Ga]GaHBED-CC-azepin-MetMAb was formulated in sterile PBS for in vivo experiments 169 
(RCP>95%, radio-SEC analysis, Figure 1C, black trace). Formulated [68Ga]GaHBED-CC-azepin-170 
MetMAb was isolated with a molar activity Am = 22.3 MBq nmol-1 and an isolated decay-corrected 171 
radiochemical yield (RCY) of 55%. 172 
 173 
Cell culture 174 
 The human prostate cancer cell line PC-3 (c-MET +ve moderate expressing, ATCC) and 175 
the human gastric cancer cell line MKN-45 (c-MET +ve high expressing, DKMZ) were used for 176 




used as a control in vitro for Western blot analysis. Full cell culture methods are presented in the 178 
supporting information.  179 
 180 
Western blot analysis  181 
  182 
Figure 2. Western blot images showing the MET content of three cell lysates: LNCaP (negative 183 
control), PC-3 and MKN-45. 184 
  185 
Western blot analysis of normalised protein concentration cell lysates (LNCaP, PC-3, 186 
MKN-45), shown in Figure 2, indicated that the negative control LNCaP lysate contained no c-187 
MET, the PC-3 lysate contained a low/moderate amount of c-MET, and the MKN-45 cell lysate 188 
had a very high c-MET protein content (Figure 2). Full details of the Western blot technique are 189 
presented in the supporting information. The two bands present for MET protein correspond to 190 
precursor-MET (»175 kDa) and mature-MET (»145 kDa) as previously described.27 Due to 191 
variations in the concentrations of “housekeeping” proteins between different cell lines, two 192 
loading controls were used (α-tubulin and β-actin). Although significant differences were seen in 193 
the α-tubulin bands, β-actin bands appeared consistent for the three cell lines.  194 
 195 




 The immunoreactive fraction (IF) was determined in vitro using two different cell lines 197 
with either high (MKN-45) or low/moderate (PC-3) c-MET expression. The saturation binding 198 
plot and the corresponding Lindmo reciprocal plot for the MKN-45 line are presented in 199 
Supporting Figure 3. Standard Lindmo assays confirmed that [68Ga]GaHBED-CC-azepin-200 
MetMAb remained immunoreactive and bound specifically to both MKN-45 (IF = 57±3%) and 201 
PC-3 cells (IF = 41±2%).28 It should be noted that the number of cells required to achieve a non-202 
linear binding profile for the PC-3 line was three times higher (33x106) than for the MKN-45 line 203 
(11x106). The lower c-MET concentration (as observed by Western blot analysis, Figure 2) leads 204 
to slower binding kinetics, and therefore, saturation binding is not reached under the experimental 205 
conditions which explains the relatively lower immunoreactive fraction. Full protocols for cellular 206 
binding studies are given in the supporting information.  207 
Irradiation of a biomolecule with UV light is potentially detrimental to its biological 208 
activity. Therefore, experiments to determine if irradiation at 365 nm affected the 209 
immunoreactivity of a bioconjugate were conducted. For these experiments we employed DFO-210 
NCS-MetMAb as a model conjugate that was produced via a conventional protein ligation route. 211 
p-NCS-Bz-DFO (CheMatech) was coupled to MetMAb using standard thiourea chemistry.29 212 
Aliquots of the purified conjugate were irradiated with 365 nm light at 100% LED intensity for 213 
10, 30, or 60 min. Each sample was radiolabeled with 68Ga and incubated with a fixed number of 214 
cells (5 x 106). The cellular bound fraction of radioactivity was determined for each sample using 215 
a similar method as for cell binding studies. Measurements for specific binding were performed in 216 
triplicate. The resulting cell bound activity (including a measure of non-specific binding) is shown 217 
in Figure 3. Furthermore, no discernable difference was observed between the measured 218 




(IF = 57±3%, Supporting Figure 3) and that produced from the conventional conjugation route 220 
(63±5%, SF3). No statistically significant difference (n = 3, P-value > 0.1) was found between the 221 
different aliquots, indicating that irradiation at 365 nm does not affect the immunoreactivity of the 222 
MetMAb bioconjugate. It should still be considered that biomolecules do not always behave 223 
analogously, and therefore, stability of proteins towards irradiation at 365 nm should be assessed 224 
on an individual case basis. 225 
 226 
Figure 3. Plot showing the cell-associated fraction of [68Ga]GaDFO-NCS-MetMAb after 227 
irradiation at 365 nm for different times. 228 
 229 
Serum stability  230 
 The stability of [68Ga]GaHBED-CC-azepin-MetMAb with respect to loss of radioactivity 231 
from the protein fraction or a change in RCP was investigated by incubation of the radiotracer in 232 
human serum albumin (HSA, Sigma Aldrich) at 37 °C. Stability studies (n = 2) were analysed 233 
using radio-SEC and showed that only a small amount of radioactivity (< 5%) was lost from the 234 
antibody over the course of 3 h (Figure 4A).  235 



























Figure 4. Stability data showing: A) radio-SEC chromatograms of [68Ga]GaHBED-CC-azepin-237 
MetMAb incubated in HSA over 3 h at 37 oC. 238 
 239 
  240 
 241 
Small animal PET Imaging 242 
 PET imaging was conducted in groups of mice bearing either MKN-45 (n = 5) or PC-3 (n 243 
= 3) tumours between 4 – 6 h post-administration of [68Ga]GaHBED-CC-azepin-MetMAb. Mice 244 
were administered either a high molar activity formulation of [68Ga]GaHBED-CC-azepin-245 
MetMAb (normal group, Am = 22.3 MBq nmol-1, 8.26 – 11.33 MBq, 50 – 60 µg in 220 µL PBS) 246 
or a low molar activity formulation of [68Ga]Ga HBED-CC-azepin-MetMAb (blocking 247 
competitively blocked group, Am = 1.26 MBq nmol-1, 8.83 – 9.57 MBq, 1050 – 1060 µg [16.7 fold 248 
excess] in 240 µL PBS) via intravenous (i.v.) tail vein injection. Full details of the competitive 249 
blocking experiment are given in the supporting information.  Shortly before imaging, mice were 250 
anaesthetised with isoflurane and static images were recorded for 10 minutes at 4, 5, and 6 h post-251 
injection time points. 252 
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Figure 5. Longitudinal maximum intensity projection (MIP) PET images recorded in the MKN-254 
45 model at 4, 5 and 6 h, and in the competitively blocked MKN-45 model at 6 h post-255 
administration of [68Ga]GaHBED-CC-azepin-MetMAb. 256 
 257 
 PET images recorded at 4, 5, and 6 h for the normal MKN-45 model, and an image at 6 h 258 
for the competitively blocked MKN-45 model are shown in Figure 5. Additionally, a PET image 259 
at 6 h in the PC-3 model is shown in Supporting Figure 5. In the normal MKN-45 model, tumours 260 
were easily visualised, although accumulation of radioactivity in the heart and lungs (which is 261 
representative of the circulating blood-pool activity in these in static PET imaging) contained the 262 
most activity. Immuno-PET imaging in MKN-45 and PC-3 models showed that the radiotracer 263 
remained in circulation (Heart ROI = 2.47±0.33 SUVmean, 6 h, normal group, n = 5, Supporting 264 
Figure 6). Tumour-to-tissue contrast ratios are presented in Supporting Figure 7. Furthermore, 265 
images showed low clearance of the tracer through the liver (Liver ROI = 1.31±0.93 SUVmean, 6 266 
h, normal group, n = 5, Supporting Figure 6). The measured effective half-life (t1/2(effective)) of 267 
[68Ga]GaHBED-CC-azepin-MetMAb was 59.9±10.8 min (n = 3, Supporting Figure 8). This value 268 




radiotracer was not excreted from the body in the experimental window. Temporal PET imaging 270 
showed increased tumour uptake in MKN-45 models (Tumour ROI, SUVmean= 1.39±0.14 (4 h) to 271 
1.57±0.15 (6 h), normal group, n = 5, Supporting Figure 6). In the competitive blocking PET 272 
images, tumour uptake remained lower and constant (Tumour ROI SUVmean = 1.04±0.10 (4 h) to 273 
1.00±0.09 (6 h), blocking group, n = 5, Supporting Figure 6). 274 
 275 
Biodistribution studies 276 
 Biodistribution studies were performed ex vivo at 6 h post-administration of 277 
[68Ga]GaHBED-CC-azepin-MetMAb in MKN-45 and PC-3 tumour-bearing mice. Immediately 278 
after recording the final image, mice were euthanised by exsanguination under anaesthesia. Tissues 279 
were removed, washed with water, dried in air, weighed and counted using a calibrated gamma 280 
counter for accumulation of 68Ga-radioactivity. Full biodistribution data sets are presented in 281 
Figure 6 and in Supporting Table S1. 282 
 283 
Figure 6. Biodistribution data showing the accumulation of [68Ga]GaHBED-CC-azepin-284 
MetMAb radioactivity in different tissues at 6 h post-administration in mice bearing either 285 
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  287 
Accumulation of radioactivity in the more highly expressing c-MET positive MKN-45 288 
tumours was 10.33±1.27 %ID/g (n = 5). This value reduced to 3.88±0.68 %ID/g (n = 3, P-value 289 
< 0.001) in moderately c-MET expressing PC-3 tumours. Furthermore, the blocking study 290 
illustrated that accumulation of [68Ga]GaHBED-CC-azepin-MetMAb in MKN-45 tumours could 291 
be reduced by ~55% to 4.62 ± 0.67 %ID/g (n = 5, P-value < 0.001) by co-administration of the 292 
radiotracer with higher concentrations of non-radiolabelled MetMAb. Hence, the blocking study 293 
confirmed the specific targeting of c-MET by [68Ga]GaHBED-CC-azepin-MetMAb in vivo. 294 
Immuno-PET imaging and subsequent biodistribution studies of moderately c-MET expressing 295 
tumours (PC-3) as a control model resulted in only low accumulation (3.88 ± 0.68 ID/g) in tumour 296 
tissues. The observed low tumour uptake in the PC-3 model substantiates the results of earlier cell 297 
binding studies and provides further support that the PC-3 model has an insufficient c-MET 298 
concentration for optimal visualisation by immuno-PET using a radiotracer based on MetMAb.  299 
We note that the combination of the short-lived 68Ga radionuclide with higher molecular 300 
weight protein is clearly sub-optimal. Nevertheless, the PET and biodistribution data demonstrate 301 
that it is possible to image tumours that express high levels of c-MET with [68Ga]GaHBED-CC-302 
azepin-MetMAb at early time points. Our experiments confirm that the photoradiosynthesis 303 
approach can produce a viable radiotracer using engineered proteins that are smaller than native 304 
IgG antibodies. Experiments are underway to expanding the scope of photoradiochemistry using 305 
different chelates that facilitate labelling with radionuclides such as 64Cu, 89Zr, 90Y, 177Lu and 225Ac 306 
etc. Furthermore, it is possible that the HBED-CC-azepin-MetMAb conjugate could be labelled 307 
with the longer-lived radionuclide 67Ga (t1/2 = 78.3 h) and investigated as a single-photon emission 308 




ligand is also known to complex 111In3+ (t1/2 = 67.3 h, log b = 39.66) for similar applications in 310 
SPECT and RIT. The side chain modification of HBED-CC-PEG3-ArN3 is unlikely to affect  311 
coordination to 111In3+ ions.32 The longer half-lives of the proposed tracers, [67Ga]GaHBED-CC-312 
azepin-MetMAb and [111In]InHBED-CC-azepin-MetMAb, could allow greater tumour to tissue 313 
contrast ratios to be obtained by imaging at later time points.  314 
 315 
Conclusions  316 
 The synthesis of photoactivatable HBED-CC-PEG3-ArN3 allowed rapid and efficient 317 
conjugation to MetMAb. Stability studies in vitro and in vivo demonstrated the viability and 318 
selectivity of [68Ga]GaHBED-CC-azepin-MetMab as an immuno-PET radiotracer and confirmed 319 
that photoradiosynthesis can be applied with engineered proteins with molecular weights lower 320 
than native immunoglobulins. Immuno-PET with [68Ga]GaHBED-CC-azepin-MetMAb 321 
successfully delineated tumours expressing high levels of c-MET (MKN-45, 10.33 ± 1.27 %ID/g, 322 
n = 5) and blocking studies confirmed the specificity of the tumor-associated activity. Overall, 323 
these data suggest that the combination of photochemistry and radiochemistry is a viable strategy 324 
in the design of radiotracers for immuno-PET.  325 
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